Business Context and Reporting Period
Company: Phibro Animal Health Corporation (PAHC)
Filing Type: Form 10-Q (Unaudited)
Reporting Period: Three and six months ended December 31, 2025
Business Overview: A global developer, manufacturer, and marketer of animal health and mineral nutrition products for food and companion animals, as well as performance products for personal care and industrial chemical industries. The company operates through three segments: Animal Health, Mineral Nutrition, and Performance Products.
Key Financial Metrics
| Metric (in thousands) | Three Months Ended Dec 31, 2025 | Six Months Ended Dec 31, 2025 |
|---|---|---|
| Net Sales | $373,910 | $737,803 |
| Gross Profit | $132,656 | $252,439 |
| Gross Margin | 35.5% | 34.2% |
| Operating Income | $50,326 | $101,586 |
| Net Income | $27,459 | $53,986 |
| Diluted EPS | $0.67 | $1.32 |
| Adjusted EBITDA | $68,064 | $129,922 |
| Cash and Cash Equivalents | $55,486 | $55,486 |
| Total Debt (Current + Long-term) | $624,240 | $624,240 |
| Working Capital | $525,945 | $525,945 |
Material Changes vs. Prior Period
- Revenue Growth: Net sales increased 21% ($64.6M) for the quarter and 30% ($168.1M) for the six months compared to the prior year periods. This growth was primarily driven by the Animal Health segment, which saw a 26% quarterly increase and 39% six-month increase.
- Acquisition Impact: The October 31, 2024, acquisition of Zoetis's medicated feed additives (MFA) portfolio contributed $94.1M in revenue for the quarter and $174.6M for the six months ended December 31, 2025.
- Profitability: Operating income surged 97% for the quarter and 135% for the six months. Net income increased significantly from $3.2M to $27.5M (quarterly) and $10.2M to $54.0M (six months).
- Foreign Currency: Foreign currency losses decreased significantly, dropping from $11.7M to $2.1M for the quarter and $12.1M to $5.1M for the six months, largely due to reduced volatility in the Brazilian Real compared to the prior year.
- Interest Expense: Net interest expense increased 31% for the quarter and 43% for the six months due to higher debt levels financing the acquisition and the expiration of a favorable interest rate swap.
Guidance, Outlook, and Risks
Management Commentary: Management attributes strong performance to the successful integration of the Zoetis acquisition, favorable product mix, and price increases. The "Phibro Forward" initiative continues to drive cost savings and revenue growth. The company maintains confidence in meeting supply commitments despite regional conflicts.
Dividends: The Board declared a quarterly cash dividend of $0.12 per share on Class A and Class B common stock, payable March 25, 2026.
Key Risks and Contingencies:
- Geopolitical Conflict: Ongoing hostilities in Israel (where the company has three manufacturing sites representing 16% of consolidated assets) and the Russia-Ukraine conflict pose risks to supply chains, logistics, and personnel safety.
- Regulatory Actions: The FDA is reviewing the regulatory method for carbadox (Mecadox), a key product. While currently available, a potential withdrawal of approval could adversely affect financial results. Additionally, Brazil's Ministry of Agriculture is reviewing the use of virginiamycin as a growth promoter.
- Debt Covenants: The company is subject to financial covenants under its 2024 Credit Agreement, including a maximum Net Leverage Ratio (currently 4.75:1.00) and minimum interest coverage ratio. Management believes it is in compliance.
Investor Verification Checklist
- Acquisition Integration: Verify the ongoing contribution of the Zoetis MFA portfolio to revenue and the timeline for realizing full cost synergies.
- Regulatory Status of Mecadox: Monitor FDA proceedings regarding the carbadox regulatory method and potential impact on the $22M annual sales of this product.
- Geopolitical Exposure: Assess the operational resilience of Israeli manufacturing facilities (16% of assets) amidst regional instability.
- Debt Servicing: Review the impact of rising interest rates and the expiration of hedging instruments on future interest expense and cash flow.
- Inventory Levels: Note the $73.2M cash outflow for inventory during the six-month period; verify if this aligns with forecasted demand or indicates potential overstocking.